ArticleOncology letters2017
The effect of royal jelly on the growth of breast cancer in mice.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Royal jelly and its hormonal effects in breast cancer: a literature review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Pooled it
- Chemical Markers and Bioactivity of Algerian Royal Jelly: Influence of Bee Subspecies, Geography, and Lyophilization.Chemistry & biodiversity · 2026Article
- Effects of royal jelly on ovary cancer cells proliferation and apoptosis.Medical oncology (Northwood, London, England) · 2025Article
- Royal jelly with ellagic acid inhibits the glycolytic pathway and induces apoptosis through multiple pathways in colorectal cancer.Turkish journal of biology = Turk biyoloji dergisi · 2025Article
- Article
- Royal jelly a promising therapeutic intervention and functional food supplement: A systematic review.Heliyon · 2024Review
- Bee-Inspired Healing: Apitherapy in Veterinary Medicine for Maintenance and Improvement Animal Health and Well-Being.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Royal Jelly: Biological Action and Health Benefits.International journal of molecular sciences · 2024Review
- Hive Products: Composition, Pharmacological Properties, and Therapeutic Applications.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Exploring the Potential of Bee-Derived Antioxidants for Maintaining Oral Hygiene and Dental Health: A Comprehensive Review.Antioxidants (Basel, Switzerland) · 2023Review
- Differential Apoptotic Effects of Bee Product Mixtures on Normal and Cancer Hepatic Cells.Antioxidants (Basel, Switzerland) · 2023Article
- Current Status of the Bioactive Properties of Royal Jelly: A Comprehensive Review with a Focus on Its Anticancer, Anti-Inflammatory, and Antioxidant Effects.Molecules (Basel, Switzerland) · 2023Review
- Royal Jelly: Beneficial Properties and Synergistic Effects with Chemotherapeutic Drugs with Particular Emphasis in Anticancer Strategies.Nutrients · 2022Review
- Royal Jelly as a Nutraceutical Natural Product with a Focus on Its Antibacterial Activity.Pharmaceutics · 2022Review
- Antitumor Activity of Royal Jelly and Its Cellular Mechanisms against Ehrlich Solid Tumor in Mice.BioMed research international · 2022Article
- Possible therapeutic effect of royal jelly on endometriotic lesion size, pain sensitivity, and neurotrophic factors in a rat model of endometriosis.Physiological reports · 2021Article
- Pharmaceutical Prospects of Bee Products: Special Focus on Anticancer, Antibacterial, Antiviral, and Antiparasitic Properties.Antibiotics (Basel, Switzerland) · 2021Review
- Thymoquinone anticancer activity is enhanced when combined with royal jelly in human breast cancer.World journal of clinical oncology · 2021Article
- Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial.Molecular and clinical oncology · 2020Article
- Royal jelly mitigates cadmium-induced neuronal damage in mouse cortex.Molecular biology reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to various pharmacological properties, including antioxidative, anti-inflammatory and antibiotic properties, royal jelly (RJ) has been widely consumed in daily diets in numerous countries. In the present study, the effect of RJ on 4T1-bearing mice was investigated. The study was performed by feeding 4T1-bearing mice with RJ using either the prophylactic-therapeutic (PTRJ) or therapeutic (TRJ) method. The experimental results for the PTRJ group demonstrated that the weight of tumor was significantly reduced (RJ 0.5 and 1.5 g/kg); and in the serum, the levels of interleukin (IL)-2 (RJ 0.5 and 1.5 g/kg), interferon (IFN)-α, superoxide dismutase (SOD) and total antioxidant capacity (T-AOC) were significantly elevated, but the concentrations of IL-4 (RJ 0.5 and 1.5 g/kg) and IL-10 (RJ 1.0 g/kg) were significantly decreased. In addition, the activities of T-AOC and glutathione reductase (GR) were significantly improved in the liver, whereas in the kidney, the activities of T-AOC and GR were significantly increased only under the dose of 0.5 g/kg. For the TRJ group, the antitumor effect of RJ was not significant; the change in IL-2, IFN-α, SOD and T-AOC levels in the serum, and the change in T-AOC and GR in liver were similar to those observed in the PTRJ groups. RJ treatment was demonstrated to reduce the development of breast tumor in mice, and simultaneously improve the antioxidant capacity of the serum, liver and kidney, particularly using the prophylactic-therapeutic method. These results corroborated the efficacy of RJ supplementation in diets. The results of the present study suggest that the antioxidant and immunomodulatory activities of RJ serve an important role on antitumor growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.